A Phase I/II Study of Gleevec Combined With Panitumumab (Vectibix) in Patients Prescreened for c-Kit/PDGFr Activated Pathways Using a Proteomic Based Assay.

Trial Profile

A Phase I/II Study of Gleevec Combined With Panitumumab (Vectibix) in Patients Prescreened for c-Kit/PDGFr Activated Pathways Using a Proteomic Based Assay.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Sep 2013

At a glance

  • Drugs Imatinib (Primary) ; Panitumumab
  • Indications Cancer metastases; Colorectal cancer
  • Focus Adverse reactions
  • Acronyms NITMEC
  • Most Recent Events

    • 23 Mar 2012 Actual patient number 10 added as reported by ClinicalTrials.gov.
    • 12 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Trial design presented as a poster at the 2010 annual meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top